ASH 2023 | The emerging role of MRD in assessing response to CAR T-cell therapy and TCE in R/R multiple myeloma
Aintzane Zabaleta, University of Navarra, Pamplona, Spain, evaluates the use of measurable residual disease (MRD) in multiple myeloma (MM). Since CAR T-cell therapy and T-cell engagers (TCE) are now approved for relapsed/ refractory (R/R) MM, it is necessary to consider their use in new R/R MM cases; assessing the use of MRD is vital in determining which patients to allocate to therapies they are most likely to respond to. The results of the KarMMa trial (NCT03361748) are interesting in this case, as they show both MRD and depth of response to be valuable in determining prognoses of rare MM disease cases, unlike many findings suggesting MRD surpasses other prognostic factors in other cancers. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
